Sage Journals: Discover world-class research

Abstract

Rationale

Cryptogenic ischemic strokes constitute 20–30% of ischemic strokes, the majority of which are embolic strokes of undetermined source. The standard preventive treatment in these patients is usually acetylsalicylic acid.

Aim

The Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS) is designed to determine whether the oral thrombin inhibitor dabigatran, taken within three-months after embolic stroke of undetermined source, is superior to acetylsalicylic acid for prevention of recurrent stroke and to characterize the safety of dabigatran in this setting.

Design

Prospective, randomized, double-blind, multicenter trial in approximately 6000 patients and 550 centers with embolic stroke of undetermined source. Subjects are randomized to dabigatran or acetylsalicylic acid and treated for an expected minimum of six-months and up to approximately three-years. It is an event-driven trial aiming for 353 adjudicated primary outcome events.

Study outcomes

The primary efficacy outcome is time to first recurrent stroke (ischemic, hemorrhagic, or unspecified). Key secondary outcomes are time to first ischemic stroke and time to first occurrence in the composite outcome of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death. The primary safety outcome is major hemorrhage, including symptomatic intracranial hemorrhage.

Discussion

Acetylsalicylic acid is the most common antithrombotic given to patients with embolic strokes of undetermined source to reduce recurrence risk. This trial will determine whether anticoagulation with dabigatran is more effective than acetylsalicylic acid, and acceptably safe.

Keywords

acetylsalicylic acid (ASA)clinical trial dabigatran minor stroke stroke prevention transient ischemic attack (TIA)

Get full access to this article

View all access options for this article.

References

1 Adams

Jr Bendixen

Kappelle

. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10 172 in Acute Stroke Treatment. Stroke 1993; 24:35–41.

2 Fonseca

Ferro

. Cryptogenic stroke. Eur J Neurol 2015; 22:618–23.

3 Ntaios

Papavasileiou

Milionis

. Embolic strokes of undetermined source in the Athens Stroke Registry: a descriptive analysis. Stroke 2015; 46:176–81.

4 Sacco

Ellenberg

Mohr

. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol 1989; 25:382–90.

5 Hart

Pearce

Aguilar

. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857–67.

6 Kernan

Ovbiagele

Black

. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45:2160–236.

7 Hart

Diener

Coutts

. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13:429–38.

8 Sacco

Prabhakaran

Thompson

. Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study. Cerebrovasc Dis 2006; 22:4–12.

9 Ruff

Giugliano

Braunwald

. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383:955–62.

10.

10 Connolly

Ezekowitz

Yusuf

. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139–51.

11.

11 Healey

Connolly

Gold

. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366:120–9.

12.

12 Schulman

Kearon

; Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3:692–4.

13.

13 Diener

Eikelboom

Connolly

. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 2012; 11:225–31.

14.

14 Favilla

Ingala

Jara

. Predictors of Finding Occult Atrial Fibrillation After Cryptogenic Stroke. Stroke 2015.

15.

15 Grau

Weimar

Buggle

. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 2001; 32:2559–66.

16.

16 Heidbuchel

Verhamme

Alings

. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15:625–51.

17.

17 Hahn

Hill

. Early anti-coagulation after ischemic stroke due to atrial fibrillation is safe and prevents recurrent stroke. Can J Neurol Sci 2015; 42:92–5.

18.

18 Wardlaw

Smith

Biessels

. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12:822–38.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.23 MB